Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Orphanet J Rare Dis ; 18(1): 98, 2023 04 29.
Artículo en Inglés | MEDLINE | ID: mdl-37120555

RESUMEN

BACKGROUND: This study measured sleep quality among caregivers of patients with Dravet syndrome (DS) and assessed the impacts of mental health problems and caregiver burden on sleep quality. METHODS: This multicenter, cross-sectional study of patients with DS and their caregivers throughout Germany consisted of a questionnaire and a prospective 4-week diary querying disease characteristics, demographic data, living conditions, nocturnal supervision, and caregivers' work situations. Sleep quality was assessed using the Pittsburgh Sleeping Quality Index (PSQI). The Hospital Anxiety and Depression Scale (HADS) and the Burden Scale for Family Caregivers (BSFC) were used to measure anxiety, symptoms of depression, and caregiver burden. RESULTS: Our analysis included 108 questionnaires and 82 four-week diaries. Patients with DS were 49.1% male (n = 53), with a mean age of 13.5 ± 10.0 years. Caregivers were 92.6% (n = 100) female, with a mean age of 44.7 ± 10.6 years. The overall mean PSQI score was 8.7 ± 3.5, with 76.9% of participants (n = 83) scoring 6 or higher, indicating abnormal sleep quality. The HADS for anxiety and depression had overall mean scores of 9.3 ± 4.3 and 7.9 ± 3.7, respectively; 61.8% and 50.9% of participants scored above the cutoff value of 8 for anxiety and depression, respectively. Statistical analyses revealed caregiver anxiety levels and patients' sleep disturbances as major factors influencing PSQI scores. The overall mean BSFC score of 41.7 ± 11.7 indicates a moderate burden, with 45.3% of caregivers scoring 42 or higher. CONCLUSIONS: Sleep quality is severely affected among caregivers of patients with DS, correlating with anxiety, comorbidities, and patients' sleep disturbances. A holistic therapeutic approach should be implemented for patients with DS and their caregivers, focusing on the sleep quality and mental health of caregivers. TRIAL REGISTRATION: German Clinical Trials Register (DRKS), DRKS00016967. Registered 27 May 2019, http://www.drks.de/DRKS00016967.


Asunto(s)
Epilepsias Mioclónicas , Trastornos del Sueño-Vigilia , Humanos , Masculino , Femenino , Preescolar , Niño , Adolescente , Adulto Joven , Adulto , Persona de Mediana Edad , Calidad de Vida/psicología , Carga del Cuidador , Calidad del Sueño , Depresión/psicología , Estudios Transversales , Estudios Prospectivos , Ansiedad , Cuidadores/psicología , Encuestas y Cuestionarios , Alemania , Atención al Paciente
2.
Am J Hum Genet ; 97(6): 894-903, 2015 Dec 03.
Artículo en Inglés | MEDLINE | ID: mdl-26637979

RESUMEN

SLC39A8 is a membrane transporter responsible for manganese uptake into the cell. Via whole-exome sequencing, we studied a child that presented with cranial asymmetry, severe infantile spasms with hypsarrhythmia, and dysproportionate dwarfism. Analysis of transferrin glycosylation revealed severe dysglycosylation corresponding to a type II congenital disorder of glycosylation (CDG) and the blood manganese levels were below the detection limit. The variants c.112G>C (p.Gly38Arg) and c.1019T>A (p.Ile340Asn) were identified in SLC39A8. A second individual with the variants c.97G>A (p.Val33Met) and c.1004G>C (p.Ser335Thr) on the paternal allele and c.610G>T (p.Gly204Cys) on the maternal allele was identified among a group of unresolved case subjects with CDG. These data demonstrate that variants in SLC39A8 impair the function of manganese-dependent enzymes, most notably ß-1,4-galactosyltransferase, a Golgi enzyme essential for biosynthesis of the carbohydrate part of glycoproteins. Impaired galactosylation leads to a severe disorder with deformed skull, severe seizures, short limbs, profound psychomotor retardation, and hearing loss. Oral galactose supplementation is a treatment option and results in complete normalization of glycosylation. SLC39A8 deficiency links a trace element deficiency with inherited glycosylation disorders.


Asunto(s)
Proteínas de Transporte de Catión/genética , Trastornos Congénitos de Glicosilación/genética , Enanismo/genética , Manganeso/sangre , Espasmos Infantiles/genética , Secuencia de Aminoácidos , Secuencia de Carbohidratos , Proteínas de Transporte de Catión/deficiencia , Cationes Bivalentes , Trastornos Congénitos de Glicosilación/sangre , Trastornos Congénitos de Glicosilación/complicaciones , Trastornos Congénitos de Glicosilación/dietoterapia , Enanismo/sangre , Enanismo/complicaciones , Enanismo/dietoterapia , Femenino , Galactosa/uso terapéutico , Expresión Génica , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Lactante , Transporte Iónico , Manganeso/deficiencia , Datos de Secuencia Molecular , Mutación , Linaje , Alineación de Secuencia , Espasmos Infantiles/sangre , Espasmos Infantiles/complicaciones , Espasmos Infantiles/dietoterapia
3.
Neurosci Lett ; 393(2-3): 206-10, 2006 Jan 30.
Artículo en Inglés | MEDLINE | ID: mdl-16246492

RESUMEN

Sensory gating refers to the ability of the brain to inhibit irrelevant sensory input. In several studies, a pathogenic role of the CHRNA7 gene and the CHRNA7-like gene, respectively, is suggested. In linkage analysis concerning familial centrotemporal spikes and sharp waves (CTS) and benign rolandic epilepsy, evidence for linkage was found to a region on chromosome 15q14, close to the alpha-7 subunit gene of the neuronal nicotinic acetylcholine receptor (CHRNA7). According to these findings, P50 evoked potentials to paired click stimuli were studied in 13 children with CTS in the EEG to determine whether they had normal sensory gating. The control group consisted of 13 healthy probands matched for gender and age. Children with CTS showed a significant sensory gating deficit (p=0.001). These results (1) suggest an inhibitory deficit in early pre-attentive auditory sensory processing in children with CTS and (2) confirm the assumption of a cholinergic pathology in CTS.


Asunto(s)
Electroencefalografía , Epilepsia Rolándica/fisiopatología , Potenciales Evocados Auditivos/fisiología , Lóbulo Temporal/fisiopatología , Estimulación Acústica/métodos , Adolescente , Anticonvulsivantes/uso terapéutico , Estudios de Casos y Controles , Niño , Epilepsia Rolándica/tratamiento farmacológico , Potenciales Evocados Auditivos/efectos de los fármacos , Femenino , Humanos , Masculino , Lóbulo Temporal/efectos de los fármacos , Tiazinas/uso terapéutico
4.
Muscle Nerve ; 25(4): 593-600, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11932978

RESUMEN

1H magnetic resonance spectroscopy (MRS) of the brain and (31)P MRS and saturation transfer of resting skeletal muscle were used to investigate intracellular metabolites and fluxes through the creatine kinase (CK) reaction in a patient with the syndrome of mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Acute cortical lesions were characterized by severely elevated lactate levels and reduced concentrations of N-acetylaspartyl compounds, glutamate, and myo-inositol. Similar but less extreme alterations were also observed in gray matter regions that appeared normal on magnetic resonance images. Investigation of the gastrocnemius muscle at rest demonstrated a reduced phosphocreatine level, elevated concentrations of inorganic phosphate and free adenosine 5'-diphosphate, and an abnormally low phosphorylation potential. Besides a moderately increased muscular phosphocreatine concentration, none of the metabolic disturbances detected on MRS improved with oral creatine supplementation. Forward and reverse fluxes through the CK reaction did not significantly change upon creatine treatment. Follow-up MRS investigations may thus provide objective markers of treatment response in vivo without the hazards or inconvenience of biopsy.


Asunto(s)
Ácido Aspártico/análogos & derivados , Encéfalo/metabolismo , Síndrome MELAS/metabolismo , Espectroscopía de Resonancia Magnética , Músculo Esquelético/fisiopatología , Adolescente , Ácido Aspártico/metabolismo , Encéfalo/fisiopatología , Creatina/uso terapéutico , Femenino , Ácido Glutámico/metabolismo , Humanos , Inositol/metabolismo , Ácido Láctico/metabolismo , Síndrome MELAS/fisiopatología , Fosfocreatina/metabolismo , Fósforo/metabolismo , Fosforilación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA